ARGX-111 shows activity in MET-amplified patients in a phase-I study and in preclinical models of myeloid-derived suppressor cell (MDSC) depletion in the tumor microenvironment. This is an ASCO ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback